PERFORMANCE STATUS AND COMORBIDITY AFFECT SURVIVAL IN ELDERLY PATIENTS WITH CLL AFTER LOW DOSE ALEMTUZUMAB COMBINED WITH CHEMOTHERAPY: RESULTS FROM THE HOVON68 TRIAL

Authors
Publication date
30 June 2016
Publisher

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    NARCIS

    redirect
    Last time updated on 29/05/2021